Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.37 |
| ▸ | FNTB | P49356 | 3/20 | 0.37 |
| ▸ | DNAJA1 | P31689 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7165181 | 0.95 | FNTA (0.37) | FNTAPGGT1BFNTBDNAJA1HTR1A | |
| SCHEMBL6409378 | 0.89 | HTR1A (0.35) | FNTAPGGT1BFNTBDNAJA1HTR1A | |
| SCHEMBL6412093 | 0.87 | FNTA (0.35) | FNTAPGGT1BFNTBDNAJA1HTR1A | |
| SCHEMBL6410632 | 0.86 | HTR1A (0.35) | FNTAPGGT1BFNTBDNAJA1HTR1A | |
| Hydrochloric Acid SCHEMBL6469829 | 0.84 | FNTA (0.38) | FNTAPGGT1BFNTB | |
| SCHEMBL6448742 | 0.82 | FNTA (0.37) | FNTAPGGT1BFNTB | |
| SCHEMBL6416010 | 0.82 | FNTA (0.33) | FNTAPGGT1BFNTBDNAJA1HTR1A | |
| SCHEMBL7532834 | 0.78 | FNTA (0.43) | FNTAPGGT1BFNTB | |
| SCHEMBL3500420 | 0.78 | FNTA (0.62) | FNTAPGGT1BFNTBTDP2 | |
| SCHEMBL6411741 | 0.78 | FNTA (0.34) | FNTAPGGT1BFNTBDNAJA1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | disclosed |
| US-6562823-B1 | Inhibition of farnesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar | MERCK & CO., INC. | 2003-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | FNTA 4/4885PGGT1B 274/4885FNTB 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.